nodes	percent_of_prediction	percent_of_DWPC	metapath
Levetiracetam—ABCC2—Sorafenib—liver cancer	0.267	0.469	CbGbCtD
Levetiracetam—ABCC2—Doxorubicin—liver cancer	0.162	0.285	CbGbCtD
Levetiracetam—ABCC2—bile canaliculus—liver cancer	0.119	0.627	CbGeAlD
Levetiracetam—ABCB1—Sorafenib—liver cancer	0.0869	0.153	CbGbCtD
Levetiracetam—ABCB1—Doxorubicin—liver cancer	0.0527	0.0928	CbGbCtD
Levetiracetam—ABCC2—bile duct—liver cancer	0.0371	0.196	CbGeAlD
Levetiracetam—ABCC2—bile—liver cancer	0.0285	0.151	CbGeAlD
Levetiracetam—ABCC2—liver—liver cancer	0.00232	0.0123	CbGeAlD
Levetiracetam—ABCC2—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00209	0.0576	CbGpPWpGaD
Levetiracetam—ABCC2—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00206	0.0566	CbGpPWpGaD
Levetiracetam—ABCB1—embryo—liver cancer	0.0018	0.00953	CbGeAlD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—GJB1—liver cancer	0.00168	0.0461	CbGpPWpGaD
Levetiracetam—ABCC2—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00124	0.0341	CbGpPWpGaD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.0012	0.0331	CbGpPWpGaD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00118	0.0325	CbGpPWpGaD
Levetiracetam—Alopecia—Sorafenib—liver cancer	0.00113	0.00549	CcSEcCtD
Levetiracetam—Amblyopia—Doxorubicin—liver cancer	0.00113	0.00548	CcSEcCtD
Levetiracetam—Fungal infection—Doxorubicin—liver cancer	0.00113	0.00548	CcSEcCtD
Levetiracetam—Blood disorder—Epirubicin—liver cancer	0.00113	0.00547	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—GLUL—liver cancer	0.00113	0.031	CbGpPWpGaD
Levetiracetam—Mental disorder—Sorafenib—liver cancer	0.00112	0.00544	CcSEcCtD
Levetiracetam—Otitis media—Doxorubicin—liver cancer	0.00112	0.00543	CcSEcCtD
Levetiracetam—Malnutrition—Sorafenib—liver cancer	0.00111	0.00541	CcSEcCtD
Levetiracetam—Gingivitis—Doxorubicin—liver cancer	0.00111	0.00539	CcSEcCtD
Levetiracetam—ABCC2—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00111	0.0304	CbGpPWpGaD
Levetiracetam—Rash pustular—Doxorubicin—liver cancer	0.00109	0.0053	CcSEcCtD
Levetiracetam—SV2A—Disease—APCS—liver cancer	0.00108	0.0296	CbGpPWpGaD
Levetiracetam—Blood disorder—Doxorubicin—liver cancer	0.00104	0.00506	CcSEcCtD
Levetiracetam—Viral infection—Epirubicin—liver cancer	0.00104	0.00506	CcSEcCtD
Levetiracetam—Skin discolouration—Epirubicin—liver cancer	0.00104	0.00506	CcSEcCtD
Levetiracetam—Thinking abnormal—Epirubicin—liver cancer	0.00103	0.00499	CcSEcCtD
Levetiracetam—Cough increased—Epirubicin—liver cancer	0.00103	0.00499	CcSEcCtD
Levetiracetam—Dyskinesia—Epirubicin—liver cancer	0.001	0.00486	CcSEcCtD
Levetiracetam—Leukopenia—Sorafenib—liver cancer	0.000998	0.00484	CcSEcCtD
Levetiracetam—ABCB1—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.000985	0.0271	CbGpPWpGaD
Levetiracetam—Cough—Sorafenib—liver cancer	0.000973	0.00472	CcSEcCtD
Levetiracetam—ABCB1—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.000968	0.0266	CbGpPWpGaD
Levetiracetam—Gait disturbance—Epirubicin—liver cancer	0.000965	0.00468	CcSEcCtD
Levetiracetam—Viral infection—Doxorubicin—liver cancer	0.000965	0.00468	CcSEcCtD
Levetiracetam—Skin discolouration—Doxorubicin—liver cancer	0.000965	0.00468	CcSEcCtD
Levetiracetam—Coordination abnormal—Epirubicin—liver cancer	0.000959	0.00465	CcSEcCtD
Levetiracetam—Neck pain—Epirubicin—liver cancer	0.000954	0.00463	CcSEcCtD
Levetiracetam—Thinking abnormal—Doxorubicin—liver cancer	0.000952	0.00462	CcSEcCtD
Levetiracetam—Cough increased—Doxorubicin—liver cancer	0.000952	0.00462	CcSEcCtD
Levetiracetam—Arthralgia—Sorafenib—liver cancer	0.000949	0.0046	CcSEcCtD
Levetiracetam—Myalgia—Sorafenib—liver cancer	0.000949	0.0046	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000942	0.00457	CcSEcCtD
Levetiracetam—Hepatocellular injury—Epirubicin—liver cancer	0.000942	0.00457	CcSEcCtD
Levetiracetam—Dyskinesia—Doxorubicin—liver cancer	0.000928	0.0045	CcSEcCtD
Levetiracetam—Infection—Sorafenib—liver cancer	0.000904	0.00438	CcSEcCtD
Levetiracetam—Gait disturbance—Doxorubicin—liver cancer	0.000893	0.00433	CcSEcCtD
Levetiracetam—Nervous system disorder—Sorafenib—liver cancer	0.000892	0.00433	CcSEcCtD
Levetiracetam—Thrombocytopenia—Sorafenib—liver cancer	0.000891	0.00432	CcSEcCtD
Levetiracetam—Coordination abnormal—Doxorubicin—liver cancer	0.000888	0.00431	CcSEcCtD
Levetiracetam—Skin disorder—Sorafenib—liver cancer	0.000884	0.00429	CcSEcCtD
Levetiracetam—Neck pain—Doxorubicin—liver cancer	0.000882	0.00428	CcSEcCtD
Levetiracetam—Hepatocellular injury—Doxorubicin—liver cancer	0.000872	0.00423	CcSEcCtD
Levetiracetam—Anorexia—Sorafenib—liver cancer	0.000867	0.00421	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—GLUL—liver cancer	0.000863	0.0237	CbGpPWpGaD
Levetiracetam—Ecchymosis—Epirubicin—liver cancer	0.000852	0.00413	CcSEcCtD
Levetiracetam—Mouth ulceration—Epirubicin—liver cancer	0.000852	0.00413	CcSEcCtD
Levetiracetam—ABCB1—liver—liver cancer	0.000835	0.00441	CbGeAlD
Levetiracetam—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000829	0.00402	CcSEcCtD
Levetiracetam—Mental disability—Epirubicin—liver cancer	0.000818	0.00397	CcSEcCtD
Levetiracetam—Dyspepsia—Sorafenib—liver cancer	0.000801	0.00388	CcSEcCtD
Levetiracetam—Decreased appetite—Sorafenib—liver cancer	0.000791	0.00384	CcSEcCtD
Levetiracetam—Mouth ulceration—Doxorubicin—liver cancer	0.000788	0.00382	CcSEcCtD
Levetiracetam—Ecchymosis—Doxorubicin—liver cancer	0.000788	0.00382	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Sorafenib—liver cancer	0.000785	0.00381	CcSEcCtD
Levetiracetam—Fatigue—Sorafenib—liver cancer	0.000784	0.0038	CcSEcCtD
Levetiracetam—Constipation—Sorafenib—liver cancer	0.000778	0.00377	CcSEcCtD
Levetiracetam—Pain—Sorafenib—liver cancer	0.000778	0.00377	CcSEcCtD
Levetiracetam—Eczema—Epirubicin—liver cancer	0.000761	0.00369	CcSEcCtD
Levetiracetam—Hepatic failure—Epirubicin—liver cancer	0.000761	0.00369	CcSEcCtD
Levetiracetam—Mental disability—Doxorubicin—liver cancer	0.000757	0.00367	CcSEcCtD
Levetiracetam—ABCC2—Irinotecan Pathway—APC—liver cancer	0.00075	0.0206	CbGpPWpGaD
Levetiracetam—Gastrointestinal pain—Sorafenib—liver cancer	0.000744	0.00361	CcSEcCtD
Levetiracetam—Body temperature increased—Sorafenib—liver cancer	0.000719	0.00349	CcSEcCtD
Levetiracetam—Abdominal pain—Sorafenib—liver cancer	0.000719	0.00349	CcSEcCtD
Levetiracetam—Renal impairment—Epirubicin—liver cancer	0.000719	0.00349	CcSEcCtD
Levetiracetam—Dermatitis bullous—Epirubicin—liver cancer	0.000716	0.00347	CcSEcCtD
Levetiracetam—Eczema—Doxorubicin—liver cancer	0.000704	0.00342	CcSEcCtD
Levetiracetam—Hepatic failure—Doxorubicin—liver cancer	0.000704	0.00342	CcSEcCtD
Levetiracetam—Lethargy—Epirubicin—liver cancer	0.000698	0.00339	CcSEcCtD
Levetiracetam—Hyponatraemia—Epirubicin—liver cancer	0.000687	0.00333	CcSEcCtD
Levetiracetam—Diplopia—Epirubicin—liver cancer	0.000684	0.00332	CcSEcCtD
Levetiracetam—Affect lability—Epirubicin—liver cancer	0.000673	0.00327	CcSEcCtD
Levetiracetam—Hypersensitivity—Sorafenib—liver cancer	0.00067	0.00325	CcSEcCtD
Levetiracetam—Renal impairment—Doxorubicin—liver cancer	0.000665	0.00323	CcSEcCtD
Levetiracetam—Dermatitis bullous—Doxorubicin—liver cancer	0.000662	0.00321	CcSEcCtD
Levetiracetam—Face oedema—Epirubicin—liver cancer	0.00066	0.0032	CcSEcCtD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000655	0.018	CbGpPWpGaD
Levetiracetam—Asthenia—Sorafenib—liver cancer	0.000653	0.00317	CcSEcCtD
Levetiracetam—Mood swings—Epirubicin—liver cancer	0.000648	0.00314	CcSEcCtD
Levetiracetam—Lethargy—Doxorubicin—liver cancer	0.000646	0.00313	CcSEcCtD
Levetiracetam—Pruritus—Sorafenib—liver cancer	0.000644	0.00312	CcSEcCtD
Levetiracetam—Ataxia—Epirubicin—liver cancer	0.000643	0.00312	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—DNAJB1—liver cancer	0.000642	0.0176	CbGpPWpGaD
Levetiracetam—Dehydration—Epirubicin—liver cancer	0.000636	0.00308	CcSEcCtD
Levetiracetam—Hyponatraemia—Doxorubicin—liver cancer	0.000635	0.00308	CcSEcCtD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—PRKCE—liver cancer	0.000634	0.0174	CbGpPWpGaD
Levetiracetam—Diplopia—Doxorubicin—liver cancer	0.000633	0.00307	CcSEcCtD
Levetiracetam—Liver function test abnormal—Epirubicin—liver cancer	0.000631	0.00306	CcSEcCtD
Levetiracetam—Abdominal pain upper—Epirubicin—liver cancer	0.000625	0.00303	CcSEcCtD
Levetiracetam—Affect lability—Doxorubicin—liver cancer	0.000623	0.00302	CcSEcCtD
Levetiracetam—Diarrhoea—Sorafenib—liver cancer	0.000622	0.00302	CcSEcCtD
Levetiracetam—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000616	0.00299	CcSEcCtD
Levetiracetam—Nasopharyngitis—Epirubicin—liver cancer	0.000612	0.00297	CcSEcCtD
Levetiracetam—Face oedema—Doxorubicin—liver cancer	0.000611	0.00296	CcSEcCtD
Levetiracetam—Muscular weakness—Epirubicin—liver cancer	0.000603	0.00293	CcSEcCtD
Levetiracetam—Dizziness—Sorafenib—liver cancer	0.000601	0.00292	CcSEcCtD
Levetiracetam—Mood swings—Doxorubicin—liver cancer	0.0006	0.00291	CcSEcCtD
Levetiracetam—Ataxia—Doxorubicin—liver cancer	0.000595	0.00289	CcSEcCtD
Levetiracetam—Asthma—Epirubicin—liver cancer	0.000591	0.00287	CcSEcCtD
Levetiracetam—Influenza—Epirubicin—liver cancer	0.000591	0.00287	CcSEcCtD
Levetiracetam—Dehydration—Doxorubicin—liver cancer	0.000589	0.00285	CcSEcCtD
Levetiracetam—Eosinophilia—Epirubicin—liver cancer	0.000585	0.00284	CcSEcCtD
Levetiracetam—Liver function test abnormal—Doxorubicin—liver cancer	0.000584	0.00283	CcSEcCtD
Levetiracetam—ABCB1—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.000584	0.016	CbGpPWpGaD
Levetiracetam—Pancreatitis—Epirubicin—liver cancer	0.00058	0.00281	CcSEcCtD
Levetiracetam—Vomiting—Sorafenib—liver cancer	0.000578	0.0028	CcSEcCtD
Levetiracetam—Abdominal pain upper—Doxorubicin—liver cancer	0.000578	0.0028	CcSEcCtD
Levetiracetam—Rash—Sorafenib—liver cancer	0.000574	0.00278	CcSEcCtD
Levetiracetam—Dermatitis—Sorafenib—liver cancer	0.000573	0.00278	CcSEcCtD
Levetiracetam—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00057	0.00276	CcSEcCtD
Levetiracetam—Headache—Sorafenib—liver cancer	0.00057	0.00276	CcSEcCtD
Levetiracetam—Bronchitis—Epirubicin—liver cancer	0.000569	0.00276	CcSEcCtD
Levetiracetam—Nasopharyngitis—Doxorubicin—liver cancer	0.000566	0.00274	CcSEcCtD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.000566	0.0156	CbGpPWpGaD
Levetiracetam—Pancytopenia—Epirubicin—liver cancer	0.000561	0.00272	CcSEcCtD
Levetiracetam—Muscular weakness—Doxorubicin—liver cancer	0.000558	0.00271	CcSEcCtD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000556	0.0153	CbGpPWpGaD
Levetiracetam—Neutropenia—Epirubicin—liver cancer	0.000553	0.00268	CcSEcCtD
Levetiracetam—Upper respiratory tract infection—Epirubicin—liver cancer	0.000549	0.00266	CcSEcCtD
Levetiracetam—Asthma—Doxorubicin—liver cancer	0.000547	0.00265	CcSEcCtD
Levetiracetam—Influenza—Doxorubicin—liver cancer	0.000547	0.00265	CcSEcCtD
Levetiracetam—Eosinophilia—Doxorubicin—liver cancer	0.000542	0.00263	CcSEcCtD
Levetiracetam—Nausea—Sorafenib—liver cancer	0.00054	0.00262	CcSEcCtD
Levetiracetam—Weight increased—Epirubicin—liver cancer	0.000538	0.00261	CcSEcCtD
Levetiracetam—Pancreatitis—Doxorubicin—liver cancer	0.000536	0.0026	CcSEcCtD
Levetiracetam—Weight decreased—Epirubicin—liver cancer	0.000535	0.00259	CcSEcCtD
Levetiracetam—Infestation—Epirubicin—liver cancer	0.000527	0.00256	CcSEcCtD
Levetiracetam—Infestation NOS—Epirubicin—liver cancer	0.000527	0.00256	CcSEcCtD
Levetiracetam—Drowsiness—Epirubicin—liver cancer	0.000527	0.00256	CcSEcCtD
Levetiracetam—Bronchitis—Doxorubicin—liver cancer	0.000526	0.00255	CcSEcCtD
Levetiracetam—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000523	0.00253	CcSEcCtD
Levetiracetam—ABCB1—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00052	0.0143	CbGpPWpGaD
Levetiracetam—Pancytopenia—Doxorubicin—liver cancer	0.000519	0.00252	CcSEcCtD
Levetiracetam—Stomatitis—Epirubicin—liver cancer	0.000514	0.00249	CcSEcCtD
Levetiracetam—Conjunctivitis—Epirubicin—liver cancer	0.000512	0.00248	CcSEcCtD
Levetiracetam—Urinary tract infection—Epirubicin—liver cancer	0.000512	0.00248	CcSEcCtD
Levetiracetam—Neutropenia—Doxorubicin—liver cancer	0.000511	0.00248	CcSEcCtD
Levetiracetam—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000508	0.00247	CcSEcCtD
Levetiracetam—Hepatobiliary disease—Epirubicin—liver cancer	0.000498	0.00242	CcSEcCtD
Levetiracetam—Weight increased—Doxorubicin—liver cancer	0.000498	0.00241	CcSEcCtD
Levetiracetam—Epistaxis—Epirubicin—liver cancer	0.000497	0.00241	CcSEcCtD
Levetiracetam—Weight decreased—Doxorubicin—liver cancer	0.000495	0.0024	CcSEcCtD
Levetiracetam—Sinusitis—Epirubicin—liver cancer	0.000494	0.0024	CcSEcCtD
Levetiracetam—Agranulocytosis—Epirubicin—liver cancer	0.000492	0.00239	CcSEcCtD
Levetiracetam—Drowsiness—Doxorubicin—liver cancer	0.000488	0.00237	CcSEcCtD
Levetiracetam—Infestation—Doxorubicin—liver cancer	0.000488	0.00237	CcSEcCtD
Levetiracetam—Infestation NOS—Doxorubicin—liver cancer	0.000488	0.00237	CcSEcCtD
Levetiracetam—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000484	0.00235	CcSEcCtD
Levetiracetam—Stomatitis—Doxorubicin—liver cancer	0.000475	0.00231	CcSEcCtD
Levetiracetam—Rhinitis—Epirubicin—liver cancer	0.000474	0.0023	CcSEcCtD
Levetiracetam—Urinary tract infection—Doxorubicin—liver cancer	0.000474	0.0023	CcSEcCtD
Levetiracetam—Conjunctivitis—Doxorubicin—liver cancer	0.000474	0.0023	CcSEcCtD
Levetiracetam—Hepatitis—Epirubicin—liver cancer	0.000473	0.00229	CcSEcCtD
Levetiracetam—Pharyngitis—Epirubicin—liver cancer	0.00047	0.00228	CcSEcCtD
Levetiracetam—Connective tissue disorder—Epirubicin—liver cancer	0.000465	0.00226	CcSEcCtD
Levetiracetam—Hepatobiliary disease—Doxorubicin—liver cancer	0.000461	0.00224	CcSEcCtD
Levetiracetam—Epistaxis—Doxorubicin—liver cancer	0.00046	0.00223	CcSEcCtD
Levetiracetam—Sinusitis—Doxorubicin—liver cancer	0.000458	0.00222	CcSEcCtD
Levetiracetam—Agranulocytosis—Doxorubicin—liver cancer	0.000455	0.00221	CcSEcCtD
Levetiracetam—Erythema multiforme—Epirubicin—liver cancer	0.000447	0.00217	CcSEcCtD
Levetiracetam—Eye disorder—Epirubicin—liver cancer	0.000442	0.00214	CcSEcCtD
Levetiracetam—Rhinitis—Doxorubicin—liver cancer	0.000439	0.00213	CcSEcCtD
Levetiracetam—Hepatitis—Doxorubicin—liver cancer	0.000438	0.00212	CcSEcCtD
Levetiracetam—Pharyngitis—Doxorubicin—liver cancer	0.000435	0.00211	CcSEcCtD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000431	0.0118	CbGpPWpGaD
Levetiracetam—Connective tissue disorder—Doxorubicin—liver cancer	0.00043	0.00209	CcSEcCtD
Levetiracetam—Immune system disorder—Epirubicin—liver cancer	0.000427	0.00207	CcSEcCtD
Levetiracetam—Mediastinal disorder—Epirubicin—liver cancer	0.000426	0.00207	CcSEcCtD
Levetiracetam—SV2A—Disease—LTF—liver cancer	0.00042	0.0115	CbGpPWpGaD
Levetiracetam—Alopecia—Epirubicin—liver cancer	0.000418	0.00203	CcSEcCtD
Levetiracetam—Mental disorder—Epirubicin—liver cancer	0.000415	0.00201	CcSEcCtD
Levetiracetam—Erythema multiforme—Doxorubicin—liver cancer	0.000414	0.00201	CcSEcCtD
Levetiracetam—Malnutrition—Epirubicin—liver cancer	0.000412	0.002	CcSEcCtD
Levetiracetam—Eye disorder—Doxorubicin—liver cancer	0.000409	0.00198	CcSEcCtD
Levetiracetam—Tension—Epirubicin—liver cancer	0.000404	0.00196	CcSEcCtD
Levetiracetam—Nervousness—Epirubicin—liver cancer	0.0004	0.00194	CcSEcCtD
Levetiracetam—Back pain—Epirubicin—liver cancer	0.000398	0.00193	CcSEcCtD
Levetiracetam—Immune system disorder—Doxorubicin—liver cancer	0.000395	0.00192	CcSEcCtD
Levetiracetam—Mediastinal disorder—Doxorubicin—liver cancer	0.000395	0.00191	CcSEcCtD
Levetiracetam—Vision blurred—Epirubicin—liver cancer	0.000388	0.00188	CcSEcCtD
Levetiracetam—Alopecia—Doxorubicin—liver cancer	0.000387	0.00188	CcSEcCtD
Levetiracetam—Mental disorder—Doxorubicin—liver cancer	0.000384	0.00186	CcSEcCtD
Levetiracetam—Malnutrition—Doxorubicin—liver cancer	0.000381	0.00185	CcSEcCtD
Levetiracetam—Agitation—Epirubicin—liver cancer	0.000379	0.00184	CcSEcCtD
Levetiracetam—Tension—Doxorubicin—liver cancer	0.000374	0.00181	CcSEcCtD
Levetiracetam—Nervousness—Doxorubicin—liver cancer	0.00037	0.0018	CcSEcCtD
Levetiracetam—Vertigo—Epirubicin—liver cancer	0.00037	0.00179	CcSEcCtD
Levetiracetam—Leukopenia—Epirubicin—liver cancer	0.000369	0.00179	CcSEcCtD
Levetiracetam—Back pain—Doxorubicin—liver cancer	0.000369	0.00179	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GSTA3—liver cancer	0.000369	0.0101	CbGpPWpGaD
Levetiracetam—Cough—Epirubicin—liver cancer	0.000359	0.00174	CcSEcCtD
Levetiracetam—Vision blurred—Doxorubicin—liver cancer	0.000359	0.00174	CcSEcCtD
Levetiracetam—Convulsion—Epirubicin—liver cancer	0.000357	0.00173	CcSEcCtD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000356	0.00979	CbGpPWpGaD
Levetiracetam—Arthralgia—Epirubicin—liver cancer	0.000351	0.0017	CcSEcCtD
Levetiracetam—Myalgia—Epirubicin—liver cancer	0.000351	0.0017	CcSEcCtD
Levetiracetam—Chest pain—Epirubicin—liver cancer	0.000351	0.0017	CcSEcCtD
Levetiracetam—Agitation—Doxorubicin—liver cancer	0.00035	0.0017	CcSEcCtD
Levetiracetam—Anxiety—Epirubicin—liver cancer	0.000349	0.00169	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000348	0.00169	CcSEcCtD
Levetiracetam—Vertigo—Doxorubicin—liver cancer	0.000342	0.00166	CcSEcCtD
Levetiracetam—Leukopenia—Doxorubicin—liver cancer	0.000341	0.00165	CcSEcCtD
Levetiracetam—Confusional state—Epirubicin—liver cancer	0.000339	0.00164	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GSTA4—liver cancer	0.000337	0.00927	CbGpPWpGaD
Levetiracetam—Infection—Epirubicin—liver cancer	0.000334	0.00162	CcSEcCtD
Levetiracetam—Cough—Doxorubicin—liver cancer	0.000333	0.00161	CcSEcCtD
Levetiracetam—Convulsion—Doxorubicin—liver cancer	0.00033	0.0016	CcSEcCtD
Levetiracetam—Nervous system disorder—Epirubicin—liver cancer	0.00033	0.0016	CcSEcCtD
Levetiracetam—Thrombocytopenia—Epirubicin—liver cancer	0.000329	0.0016	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GSTA2—liver cancer	0.000329	0.00903	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—NDRG1—liver cancer	0.000327	0.00899	CbGpPWpGaD
Levetiracetam—Skin disorder—Epirubicin—liver cancer	0.000327	0.00158	CcSEcCtD
Levetiracetam—SV2A—Disease—ALDOB—liver cancer	0.000325	0.00893	CbGpPWpGaD
Levetiracetam—Chest pain—Doxorubicin—liver cancer	0.000324	0.00157	CcSEcCtD
Levetiracetam—Arthralgia—Doxorubicin—liver cancer	0.000324	0.00157	CcSEcCtD
Levetiracetam—Myalgia—Doxorubicin—liver cancer	0.000324	0.00157	CcSEcCtD
Levetiracetam—Anxiety—Doxorubicin—liver cancer	0.000323	0.00157	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000322	0.00156	CcSEcCtD
Levetiracetam—Anorexia—Epirubicin—liver cancer	0.00032	0.00155	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GSTA1—liver cancer	0.000317	0.00872	CbGpPWpGaD
Levetiracetam—Confusional state—Doxorubicin—liver cancer	0.000314	0.00152	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—BRAF—liver cancer	0.000313	0.00861	CbGpPWpGaD
Levetiracetam—Infection—Doxorubicin—liver cancer	0.000309	0.0015	CcSEcCtD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000308	0.00847	CbGpPWpGaD
Levetiracetam—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000306	0.00149	CcSEcCtD
Levetiracetam—Nervous system disorder—Doxorubicin—liver cancer	0.000305	0.00148	CcSEcCtD
Levetiracetam—Thrombocytopenia—Doxorubicin—liver cancer	0.000305	0.00148	CcSEcCtD
Levetiracetam—Insomnia—Epirubicin—liver cancer	0.000304	0.00147	CcSEcCtD
Levetiracetam—Skin disorder—Doxorubicin—liver cancer	0.000302	0.00147	CcSEcCtD
Levetiracetam—Paraesthesia—Epirubicin—liver cancer	0.000302	0.00146	CcSEcCtD
Levetiracetam—Somnolence—Epirubicin—liver cancer	0.000299	0.00145	CcSEcCtD
Levetiracetam—Anorexia—Doxorubicin—liver cancer	0.000296	0.00144	CcSEcCtD
Levetiracetam—Dyspepsia—Epirubicin—liver cancer	0.000296	0.00144	CcSEcCtD
Levetiracetam—Decreased appetite—Epirubicin—liver cancer	0.000292	0.00142	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Epirubicin—liver cancer	0.00029	0.00141	CcSEcCtD
Levetiracetam—Fatigue—Epirubicin—liver cancer	0.00029	0.00141	CcSEcCtD
Levetiracetam—Pain—Epirubicin—liver cancer	0.000287	0.00139	CcSEcCtD
Levetiracetam—Constipation—Epirubicin—liver cancer	0.000287	0.00139	CcSEcCtD
Levetiracetam—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000283	0.00137	CcSEcCtD
Levetiracetam—Insomnia—Doxorubicin—liver cancer	0.000281	0.00136	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—NFE2L2—liver cancer	0.000279	0.00768	CbGpPWpGaD
Levetiracetam—Paraesthesia—Doxorubicin—liver cancer	0.000279	0.00135	CcSEcCtD
Levetiracetam—Feeling abnormal—Epirubicin—liver cancer	0.000277	0.00134	CcSEcCtD
Levetiracetam—Somnolence—Doxorubicin—liver cancer	0.000277	0.00134	CcSEcCtD
Levetiracetam—Gastrointestinal pain—Epirubicin—liver cancer	0.000275	0.00133	CcSEcCtD
Levetiracetam—Dyspepsia—Doxorubicin—liver cancer	0.000274	0.00133	CcSEcCtD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000271	0.00746	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000271	0.00746	CbGpPWpGaD
Levetiracetam—Decreased appetite—Doxorubicin—liver cancer	0.00027	0.00131	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000269	0.0013	CcSEcCtD
Levetiracetam—Fatigue—Doxorubicin—liver cancer	0.000268	0.0013	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GPX3—liver cancer	0.000267	0.00733	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—TGFA—liver cancer	0.000267	0.00733	CbGpPWpGaD
Levetiracetam—Pain—Doxorubicin—liver cancer	0.000266	0.00129	CcSEcCtD
Levetiracetam—Constipation—Doxorubicin—liver cancer	0.000266	0.00129	CcSEcCtD
Levetiracetam—Abdominal pain—Epirubicin—liver cancer	0.000266	0.00129	CcSEcCtD
Levetiracetam—Body temperature increased—Epirubicin—liver cancer	0.000266	0.00129	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—SERPINA1—liver cancer	0.000263	0.00722	CbGpPWpGaD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—RAF1—liver cancer	0.000261	0.00719	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—IL12A—liver cancer	0.000259	0.00712	CbGpPWpGaD
Levetiracetam—SV2A—Disease—ADAM17—liver cancer	0.000257	0.00706	CbGpPWpGaD
Levetiracetam—Feeling abnormal—Doxorubicin—liver cancer	0.000256	0.00124	CcSEcCtD
Levetiracetam—Gastrointestinal pain—Doxorubicin—liver cancer	0.000254	0.00123	CcSEcCtD
Levetiracetam—Hypersensitivity—Epirubicin—liver cancer	0.000248	0.0012	CcSEcCtD
Levetiracetam—Abdominal pain—Doxorubicin—liver cancer	0.000246	0.00119	CcSEcCtD
Levetiracetam—Body temperature increased—Doxorubicin—liver cancer	0.000246	0.00119	CcSEcCtD
Levetiracetam—SV2A—Disease—PSMA4—liver cancer	0.000241	0.00663	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PSMD10—liver cancer	0.000241	0.00663	CbGpPWpGaD
Levetiracetam—Asthenia—Epirubicin—liver cancer	0.000241	0.00117	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—BRAF—liver cancer	0.00024	0.00659	CbGpPWpGaD
Levetiracetam—Pruritus—Epirubicin—liver cancer	0.000238	0.00115	CcSEcCtD
Levetiracetam—SV2A—Disease—GOT2—liver cancer	0.000235	0.00645	CbGpPWpGaD
Levetiracetam—Diarrhoea—Epirubicin—liver cancer	0.00023	0.00112	CcSEcCtD
Levetiracetam—Hypersensitivity—Doxorubicin—liver cancer	0.000229	0.00111	CcSEcCtD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—HNF4A—liver cancer	0.000227	0.00623	CbGpPWpGaD
Levetiracetam—Asthenia—Doxorubicin—liver cancer	0.000223	0.00108	CcSEcCtD
Levetiracetam—Dizziness—Epirubicin—liver cancer	0.000222	0.00108	CcSEcCtD
Levetiracetam—Pruritus—Doxorubicin—liver cancer	0.00022	0.00107	CcSEcCtD
Levetiracetam—Vomiting—Epirubicin—liver cancer	0.000214	0.00104	CcSEcCtD
Levetiracetam—Diarrhoea—Doxorubicin—liver cancer	0.000213	0.00103	CcSEcCtD
Levetiracetam—Rash—Epirubicin—liver cancer	0.000212	0.00103	CcSEcCtD
Levetiracetam—Dermatitis—Epirubicin—liver cancer	0.000212	0.00103	CcSEcCtD
Levetiracetam—Headache—Epirubicin—liver cancer	0.000211	0.00102	CcSEcCtD
Levetiracetam—Dizziness—Doxorubicin—liver cancer	0.000206	0.000998	CcSEcCtD
Levetiracetam—SV2A—Disease—GOT1—liver cancer	0.000203	0.00557	CbGpPWpGaD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000202	0.00557	CbGpPWpGaD
Levetiracetam—CACNA1B—Neuronal System—RAF1—liver cancer	0.0002	0.00551	CbGpPWpGaD
Levetiracetam—Nausea—Epirubicin—liver cancer	0.0002	0.000968	CcSEcCtD
Levetiracetam—Vomiting—Doxorubicin—liver cancer	0.000198	0.000959	CcSEcCtD
Levetiracetam—Rash—Doxorubicin—liver cancer	0.000196	0.000951	CcSEcCtD
Levetiracetam—Dermatitis—Doxorubicin—liver cancer	0.000196	0.00095	CcSEcCtD
Levetiracetam—Headache—Doxorubicin—liver cancer	0.000195	0.000945	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GGT1—liver cancer	0.000188	0.00516	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PRKCE—liver cancer	0.000187	0.00514	CbGpPWpGaD
Levetiracetam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—liver cancer	0.000185	0.0051	CbGpPWpGaD
Levetiracetam—Nausea—Doxorubicin—liver cancer	0.000185	0.000896	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—GSTP1—liver cancer	0.000168	0.00463	CbGpPWpGaD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000167	0.0046	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—HMOX1—liver cancer	0.000166	0.00457	CbGpPWpGaD
Levetiracetam—SV2A—Disease—H2AFX—liver cancer	0.000163	0.00448	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—IL12B—liver cancer	0.000163	0.00447	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—HGF—liver cancer	0.000155	0.00426	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—GSTM1—liver cancer	0.000155	0.00426	CbGpPWpGaD
Levetiracetam—SV2A—Disease—MTHFR—liver cancer	0.000148	0.00406	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—HMOX1—liver cancer	0.000147	0.00405	CbGpPWpGaD
Levetiracetam—SV2A—Disease—TERT—liver cancer	0.000147	0.00405	CbGpPWpGaD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—HRAS—liver cancer	0.000144	0.00396	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000139	0.00382	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000132	0.00364	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000128	0.00351	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000128	0.00351	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000127	0.00349	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000127	0.00349	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.000125	0.00343	CbGpPWpGaD
Levetiracetam—SV2A—Disease—APC—liver cancer	0.000124	0.00341	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—TERT—liver cancer	0.000121	0.00333	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00012	0.0033	CbGpPWpGaD
Levetiracetam—SV2A—Disease—BRAF—liver cancer	0.000117	0.00321	CbGpPWpGaD
Levetiracetam—CACNA1B—Neuronal System—HRAS—liver cancer	0.00011	0.00303	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PIK3CD—liver cancer	0.000109	0.003	CbGpPWpGaD
Levetiracetam—SV2A—Disease—SERPINE1—liver cancer	0.000108	0.00297	CbGpPWpGaD
Levetiracetam—SV2A—Disease—RAF1—liver cancer	9.75e-05	0.00268	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	9.69e-05	0.00266	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PIK3CB—liver cancer	9.51e-05	0.00262	CbGpPWpGaD
Levetiracetam—SV2A—Disease—MTOR—liver cancer	9.51e-05	0.00262	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	9.5e-05	0.00261	CbGpPWpGaD
Levetiracetam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	9.31e-05	0.00256	CbGpPWpGaD
Levetiracetam—SV2A—Disease—CDKN1B—liver cancer	8.93e-05	0.00246	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	8.87e-05	0.00244	CbGpPWpGaD
Levetiracetam—SV2A—Disease—CTNNB1—liver cancer	8.44e-05	0.00232	CbGpPWpGaD
Levetiracetam—SV2A—Disease—CDKN1A—liver cancer	8.24e-05	0.00227	CbGpPWpGaD
Levetiracetam—SV2A—Disease—STAT3—liver cancer	7.35e-05	0.00202	CbGpPWpGaD
Levetiracetam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	7.12e-05	0.00196	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	6.98e-05	0.00192	CbGpPWpGaD
Levetiracetam—SV2A—Disease—MYC—liver cancer	6.83e-05	0.00188	CbGpPWpGaD
Levetiracetam—SV2A—Disease—TGFB1—liver cancer	6.82e-05	0.00187	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	6.53e-05	0.00179	CbGpPWpGaD
Levetiracetam—SV2A—Disease—KRAS—liver cancer	6.31e-05	0.00174	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—TGFB1—liver cancer	6.31e-05	0.00173	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	6.24e-05	0.00172	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	6.23e-05	0.00171	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—CASP3—liver cancer	6.23e-05	0.00171	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—IL2—liver cancer	6.22e-05	0.00171	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—CYCS—liver cancer	6.12e-05	0.00168	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	6.1e-05	0.00168	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	5.97e-05	0.00164	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	5.97e-05	0.00164	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PIK3CA—liver cancer	5.8e-05	0.00159	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	5.65e-05	0.00155	CbGpPWpGaD
Levetiracetam—SV2A—Disease—HRAS—liver cancer	5.37e-05	0.00148	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	5.36e-05	0.00147	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—HMOX1—liver cancer	5.32e-05	0.00146	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—VEGFA—liver cancer	5.28e-05	0.00145	CbGpPWpGaD
Levetiracetam—SV2A—Disease—IL6—liver cancer	5.14e-05	0.00141	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—TGFB1—liver cancer	4.85e-05	0.00133	CbGpPWpGaD
Levetiracetam—SV2A—Disease—AKT1—liver cancer	4.74e-05	0.0013	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	4.7e-05	0.00129	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	4.61e-05	0.00127	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—TNF—liver cancer	4.53e-05	0.00124	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—UGDH—liver cancer	4.53e-05	0.00124	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	4.36e-05	0.0012	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—PPARA—liver cancer	4.3e-05	0.00118	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—EPT1—liver cancer	4.26e-05	0.00117	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—TAT—liver cancer	4.03e-05	0.00111	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	3.89e-05	0.00107	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	3.42e-05	0.000941	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	3.19e-05	0.000878	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	3.13e-05	0.000862	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	3.07e-05	0.000845	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	2.99e-05	0.000822	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	2.98e-05	0.00082	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	2.96e-05	0.000814	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	2.89e-05	0.000795	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	2.89e-05	0.000794	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	2.88e-05	0.000791	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	2.82e-05	0.000776	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GLUL—liver cancer	2.74e-05	0.000754	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CPT1B—liver cancer	2.74e-05	0.000754	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—NR1H4—liver cancer	2.64e-05	0.000727	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	2.61e-05	0.000717	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTA3—liver cancer	2.6e-05	0.000715	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	2.5e-05	0.000688	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	2.4e-05	0.00066	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	2.39e-05	0.000658	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTA4—liver cancer	2.38e-05	0.000654	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTA2—liver cancer	2.32e-05	0.000637	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTA1—liver cancer	2.24e-05	0.000615	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	2.23e-05	0.000614	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	2.22e-05	0.000609	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—NAT2—liver cancer	2.21e-05	0.000608	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ALDOB—liver cancer	2.12e-05	0.000583	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.04e-05	0.00056	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CRABP1—liver cancer	2.02e-05	0.000556	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	2.02e-05	0.000556	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.97e-05	0.000542	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—HPGDS—liver cancer	1.77e-05	0.000486	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.66e-05	0.000457	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PSMA4—liver cancer	1.58e-05	0.000433	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PSMD10—liver cancer	1.58e-05	0.000433	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GOT2—liver cancer	1.53e-05	0.000421	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.5e-05	0.000413	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYP2E1—liver cancer	1.44e-05	0.000396	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.36e-05	0.000373	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYCS—liver cancer	1.35e-05	0.000371	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GGT1—liver cancer	1.32e-05	0.000364	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GOT1—liver cancer	1.32e-05	0.000364	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTP1—liver cancer	1.19e-05	0.000327	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—HMOX1—liver cancer	1.17e-05	0.000322	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTM1—liver cancer	1.09e-05	0.0003	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYP1A1—liver cancer	1.04e-05	0.000285	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—MTHFR—liver cancer	9.65e-06	0.000265	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PPARA—liver cancer	9.47e-06	0.00026	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PIK3CG—liver cancer	8.11e-06	0.000223	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PPARG—liver cancer	7.82e-06	0.000215	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PIK3CD—liver cancer	7.13e-06	0.000196	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ALB—liver cancer	7.04e-06	0.000193	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PIK3CB—liver cancer	6.21e-06	0.000171	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PIK3CA—liver cancer	3.79e-06	0.000104	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—AKT1—liver cancer	3.09e-06	8.51e-05	CbGpPWpGaD
